The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice.

PubWeight™: 1.22‹?› | Rank: Top 10%

🔗 View Article (PMC 2362228)

Published in Br J Cancer on March 01, 1999

Authors

U Mrowietz1, U Schwenk, S Maune, J Bartels, M Küpper, I Fichtner, J M Schröder, D Schadendorf

Author Affiliations

1: Department of Dermatology, Univeristy of Kiel, Germany.

Articles citing this

Role of chemokines in tumor growth. Cancer Lett (2007) 3.36

Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol (2002) 2.81

Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12

An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PLoS One (2010) 2.08

Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer (2009) 1.98

A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res (2008) 1.80

NF-kappaB activation in melanoma. Pigment Cell Res (2006) 1.55

c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem (2010) 1.40

The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm (2014) 1.33

The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res (2009) 1.18

Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer (2008) 1.11

Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. J Immunol (2009) 1.05

Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol (2015) 1.03

Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor. Clin Exp Metastasis (1999) 0.99

Chemokines and the microenvironment in neuroectodermal tumor-host interaction. Semin Cancer Biol (2008) 0.99

Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. Oncoimmunology (2014) 0.98

Metastasis-inducing S100A4 and RANTES cooperate in promoting tumor progression in mice. PLoS One (2010) 0.97

Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol (2010) 0.95

Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase. J Biol Chem (2011) 0.95

CCL5 as a potential immunotherapeutic target in triple-negative breast cancer. Cell Mol Immunol (2013) 0.92

Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5. Antimicrob Agents Chemother (2006) 0.89

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology (2015) 0.88

RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. Neoplasia (2015) 0.87

Human B cells express the orphan chemokine receptor CRAM-A/B in a maturation-stage-dependent and CCL5-modulated manner. Immunology (2008) 0.87

Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res (2011) 0.86

CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Melanoma Res (2007) 0.83

RANTES and fibroblast growth factor 2 in jawbone cavitations: triggers for systemic disease? Int J Gen Med (2013) 0.83

Systemic administration of platelets incorporating inactivated Sendai virus eradicates melanoma in mice. Mol Ther (2014) 0.82

Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5. Oncotarget (2016) 0.81

Modulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasis. Cancer Med (2012) 0.80

Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer. Mini Rev Med Chem (2015) 0.78

Investigation of the biological and anti-cancer properties of ellagic acid-encapsulated nano-sized metalla-cages. Int J Nanomedicine (2015) 0.76

Hyperactivated Signaling Pathways of Chemokine RANTES/CCL5 in Osteopathies of Jawbone in Breast Cancer Patients-Case Report and Research. Breast Cancer (Auckl) (2014) 0.76

Downregulation of CCR5 inhibits the proliferation and invasion of cervical cancer cells and is regulated by microRNA-107. Exp Ther Med (2015) 0.75

Articles cited by this

Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol (1994) 3.70

IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol (1993) 2.44

Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol (1995) 2.06

Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85

Regulation of the macrophage content of neoplasms by chemoattractants. Science (1983) 1.83

Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A (1991) 1.54

The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol (1996) 1.48

Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer (1994) 1.44

Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer (1988) 1.33

Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest (1992) 1.32

Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol (1997) 1.20

Regulation of interleukin 8 expression in human malignant melanoma cells. Cancer Res (1998) 1.08

Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells. J Immunol (1997) 1.08

Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice. J Immunol (1987) 1.08

Production and characterization of monoclonal antibodies against the novel neutrophil activating peptide NAP/IL-8. J Immunol (1989) 0.97

Characterization of gene regulatory elements for selective gene expression in human melanoma cells. Biochem Biophys Res Commun (1995) 0.88

Melanoma. Lancet (1996) 0.88

Detection of the chemokine RANTES in cytokine-stimulated human dermal fibroblasts. J Invest Dermatol (1995) 0.86

Melanoma, immune surveillance, and immunotherapy. J Clin Invest (1994) 0.83

Pathology and prognostic factors. Curr Opin Oncol (1993) 0.80

Articles by these authors

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70

Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science (1999) 7.86

A peptide antibiotic from human skin. Nature (1997) 7.64

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48

Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. J Biol Chem (2000) 6.19

NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut (2004) 4.39

Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med (1992) 3.20

Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol (2000) 2.66

Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem (1990) 2.23

The role of Schwann cells in the formation of "onion bulbs" found in chronic neuropathies. J Neuropathol Exp Neurol (1967) 2.13

Structure determination of a human lymphocyte derived neutrophil activating peptide (LYNAP). Biochem Biophys Res Commun (1988) 2.10

Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res (2000) 2.09

Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol (1986) 1.96

Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J Med Chem (1996) 1.93

Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin. J Invest Dermatol (1991) 1.79

Altered ratio between axon diameter and myelin sheath thickness in regenerated nerve fibers. Brain Res (1972) 1.70

Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63

Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol (1993) 1.55

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer (2002) 1.51

Changes of the ratio between myelin thickness and axon diameter in the human developing sural nerve. Acta Neuropathol (1978) 1.45

Human mast cells produce IL-8. J Immunol (1993) 1.44

Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie (2004) 1.43

Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40

[Eosinophilia-myalgia syndrome with fasciitis and interstitial myositis after L-tryptophan administration]. Z Rheumatol (1992) 1.39

TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38

Bioactive interleukin-8 is expressed in wounds and enhances wound healing. J Surg Res (2000) 1.37

Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. Br J Cancer (2002) 1.33

Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 1.30

Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res (2009) 1.29

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother (2000) 1.27

What is the 'true' function of skin? Exp Dermatol (2002) 1.26

Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum. J Clin Invest (1992) 1.25

Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A (2001) 1.24

Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. Am J Respir Cell Mol Biol (1999) 1.22

Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem (1999) 1.22

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20

IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol (1998) 1.20

Calcium potentials and tetrodotoxin-resistant sodium potentials in unmyelinated C fibres of biopsied human sural nerve. Neuroscience (1995) 1.19

Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype. Genes Immun (2004) 1.18

Biomarkers in melanoma. Ann Oncol (2009) 1.17

The CXC-chemokine neutrophil-activating peptide-2 induces two distinct optima of neutrophil chemotaxis by differential interaction with interleukin-8 receptors CXCR-1 and CXCR-2. Blood (1997) 1.17

Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes. Biochem Biophys Res Commun (1998) 1.17

Drug-resistance in human melanoma. Int J Cancer (2001) 1.15

[Ultrastructure of experimental allergic neuritis in the rabbit]. Acta Neuropathol (1970) 1.15

Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 1.14

Prostaglandin release from and formation in perfused frog intestine. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 1.13

Normative findings of electrically evoked compound action potential measurements using the neural response telemetry of the Nucleus CI24M cochlear implant system. Audiol Neurootol (2005) 1.12

[The pathogenesis of INH-neuropathy. I. Fine structural similarities and differences to wallerian degeneration]. Acta Neuropathol (1970) 1.12

[Edema and necrosis in the gray and white substance in experimental brain injury. Light and electron microscopic investigations]. Acta Neuropathol (1965) 1.12

New insights into the pathophysiology of primary acquired dacryostenosis. Ophthalmology (2001) 1.12

The ultrastructural morphology of the muscle fiber in myotonic dystrophy. Acta Neuropathol (1968) 1.11

Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Br J Cancer (2002) 1.11

[The fine structure of the neuromatous neurotization of nerve transplants]. Virchows Arch B Cell Pathol (1970) 1.11

[Surgical treatment of auditory canal exostoses]. Laryngorhinootologie (1999) 1.10

Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma. Am J Respir Crit Care Med (1997) 1.10

Polymorphonuclear leukocyte chemotaxis in psoriasis: enhancement by self-activated serum. Br J Dermatol (1980) 1.10

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10

Novel missense mutations in the glycogen-branching enzyme gene in adult polyglucosan body disease. Ann Neurol (2000) 1.09

Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer (1996) 1.09

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer (2009) 1.09

Quantification of human cells in NOD/SCID mice by duplex real-time polymerase-chain reaction. Haematologica (2001) 1.08

Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08

Acute inflammatory effects of a monocyte-derived neutrophil-activating peptide in rabbit skin. Immunology (1989) 1.08

Sentinel lymph-node biopsy in head and neck cancer. Br J Cancer (2004) 1.06

Purification, structural analysis, and function of natural ATAC, a cytokine secreted by CD8(+) T cells. J Biol Chem (1997) 1.06

Recombinant human tumor necrosis factor alpha lacks chemotactic activity for human peripheral blood neutrophils and monocytes. Biochem Biophys Res Commun (1988) 1.06

Detection of neutrophil-activating peptide NAP/IL-8 and NAP/IL-8 mRNA in human recombinant IL-1 alpha- and human recombinant tumor necrosis factor-alpha-stimulated human dermal fibroblasts. An immunocytochemical and fluorescent in situ hybridization study. J Immunol (1990) 1.05

Mapping of the gene encoding human beta-defensin-2 (DEFB2) to chromosome region 8p22-p23.1. Genomics (1997) 1.05

Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer (2001) 1.05

Expression profile of human defensins and antimicrobial proteins in oral tissues. J Oral Pathol Med (2001) 1.04

Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol (2000) 1.04

Human dendritic cells infected by Listeria monocytogenes: induction of maturation, requirements for phagolysosomal escape and antigen presentation capacity. Eur J Immunol (2000) 1.04

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer (2002) 1.03

Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer (2003) 1.03

DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett (2001) 1.03

Inflammatory properties of neutrophil-activating protein-1/interleukin 8 (NAP-1/IL-8) in human skin: a light- and electronmicroscopic study. J Invest Dermatol (1991) 1.03

Orthopaedic defects in familial dysautonomia. A review of sixty-five cases. J Bone Joint Surg Am (1971) 1.01

Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. J Immunol (1996) 1.01

Immunocytochemical localization of the chemokines RANTES and MIP-1 alpha within human platelets and their release during storage. Int Arch Allergy Immunol (1995) 1.01

Genomic organization, sequence, and transcriptional regulation of the human eotaxin gene. Biochem Biophys Res Commun (1997) 1.01

Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur J Immunol (1996) 1.00

Early myocardial disease and cramping myalgia in Becker-type muscular dystrophy: a kindred. Neurology (1979) 1.00

[Ultrastructure of unmyelinated(Remak) nerve fibers in isoniazid neuropathy]. Acta Neuropathol (1970) 0.99

The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol (1998) 0.99

Role of short-chain fatty acids in the hind gut. Vet Q (1998) 0.99

Autosomal dominant distal myopathy: further evidence of a chromosome 14 locus. Neuromuscul Disord (2001) 0.98

Proliferation of epineurial capillaries and smooth muscle cells in angiopathic peripheral neuropathy. Acta Neuropathol (1986) 0.98

Production and characterization of monoclonal antibodies against the novel neutrophil activating peptide NAP/IL-8. J Immunol (1989) 0.97

Adult polyglucosan body disease: a postmortem correlation study. Neurology (2003) 0.97

Detection of natural peptide antibiotics in human nasolacrimal ducts. Invest Ophthalmol Vis Sci (2001) 0.97

Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. Br J Dermatol (2002) 0.97

5-Oxo-eicosanoids are potent eosinophil chemotactic factors. Functional characterization and structural requirements. J Biol Chem (1995) 0.97